NEW YORK (GenomeWeb News) – Silicon Valley Biosystems today said that its in silico diagnostics laboratory has received CLIA certification from the California Department of Public Health.
The firm performs next-generation sequencing-based diagnostics on patient samples at the lab. It runs SV Bio's GermlineDx NGS interpretation platform, providing a "turnkey solution for clinical grade analysis and interpretation of single-gene, multi-gene, whole-exome, or whole-genome assays for germline indications, such as Mendelian disease diagnosis, carrier testing, hereditary cancer risk assessment, and pharmacogenomic applications," the firm said in a statement.
SV Bio also has a CLIA-certified ultra-high-throughput NGS wet lab for customers who need a complete solution, including generation of the genetic sequence, the company said.
Foster City, Calif.-based SV Bio was launched earlier this year and provides genomic data at the point of care. It and Mayo Clinic have an agreement to use each other's technologies to improve accessibility and the clinical use of next-generation sequencing for patients.